Organon & Co. (OGN)
Market Cap | 2.45B |
Revenue (ttm) | 6.29B |
Net Income (ttm) | 750.00M |
Shares Out | 259.96M |
EPS (ttm) | 2.88 |
PE Ratio | 3.28 |
Forward PE | 2.48 |
Dividend | $0.86 (9.11%) |
Ex-Dividend Date | May 12, 2025 |
Volume | 4,175,458 |
Open | 9.21 |
Previous Close | 9.25 |
Day's Range | 8.98 - 9.51 |
52-Week Range | 8.01 - 23.10 |
Beta | 0.70 |
Analysts | Hold |
Price Target | 18.00 (+90.68%) |
Earnings Date | May 1, 2025 |
About OGN
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to... [Read more]
Financial Performance
In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $18.0, which is an increase of 90.68% from the latest price.
News

OGN STOCK NOTICE: Organon & Co. has been Sued for Fraud; Investors are Notified to Contact BFA Law before July 22 Legal Deadline
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE:OGN) and certain of the Compa...

Shareholders who lost money on Organon & Co. (NYSE: OGN) Should Contact Wolf Haldenstein
NEW YORK , June 2, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Organon & Co. (NYSE: OGN) in the United Stat...

OGN CLASS NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law before July 22 Court Deadline (NYSE:OGN)
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's...

Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Organon & Co. (NYSE: OGN) in the United Sta...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN
NEW YORK , May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period li...

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Organon & Co. (OGN)
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey ...

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Organon To Contact Him Directly To Discuss Their Options

Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

OGN INVESTIGATION: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Firm
SAN DIEGO , May 20, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focu...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE:OG...

Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

Organon & Co: Cost Takeout Catalysts, Initiate Strong Buy
Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1%...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: O...

Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE:OGN...

Organon: Management Slashes Dividend - This Feels Disastrous
Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue shrinkage ...

EU drugs regulator confirms suicidal thoughts as side effect of anti hair-loss drug
The European drugs regulator said on Thursday its safety committee has confirmed suicidal thoughts as a side effect of Organon's anti hair-loss drug finasteride, following an EU-wide review of availab...